A leading Korean biotech venture called Celltrion Group shared recently that preclinical study results of regdanvimab (CT-P59) reveals a neutralizing effect against SARS-COV-2, including the…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.